Take Solutions Ltd — M&A Activity 2019

Jan 11, 2019

TAKE ® _J_ � Enabling Business Efficiencies

TECHNOLOGY ANALYTICS KNOWLEDGE ENTERPRISE

January 11, 2019

TAKE/BSE/2018-19

TAKE/NSE/2018-19

The Manager Dept. of Corporate Services-Listing Bombay Stock Exchange Limited, P. J. Towers, Dalal Street, Mumbai - 400001 Scrip Code: 532890

The Manager-Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra - Kurla Complex, Bandra (East), Mumbai - 400051 Symbol: TAKE

Sir/ Madam,

Sub: Intimation regarding proposed acquisition(s).

With reference to the captioned subject, please take note about the proposed acquisitions by TAKE Solutions Ltd, in terms of SEBI (Listing and Disclosure Obligation Requirements) Regulations, 2015, read with SEBI circular No. CIR/CFD/CMD/4/2015 dated 9[th ] September 2015. The requisite details under said circular are attached herewith as Annexure - I and II of this intimation.

We request you to take note of the aforesaid and acknowledge receipt.

Yours sincerely, For TAKE Solutions Limited Avane mg Company Secretary

Encl: As Above

• • 1, "1' ' "\ \� \'.· -�.. TAKE SOLUTIONS LIMITED · · , Registered & Corporate Office: No: 27, Tank Bund Road, Nungambakkam, Chennai - 600 034 -J!�'/ -• �-= "'::-:,-� CIN: L63090TN2000PLC046338; GSTIN: 33AABCT3684M1ZO 1 ;.'_�: • ··. . - - �-�-� ; Tel: +91 44 6611 0700/01

www. takesolutions. com

Annexure-1

Details of acquisition of KAI Research

	Details of acquisition of	Details of acquisition of	KAI Research
S.No a)	Particulars Name of the target entity and its brief details		Details KAI Research KAI is a US based niche Full service CRO and health research company No. The target entity is in Life sciences industry and is a Clinical Research Organization.
b) c)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? Industry to which the entity belongs
d) e) f) g) h)	Objects and efects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity) Any Governmental or regulatory approvals required for the acquisition Indicative time period for completion of the acquisition Nature of Consideration- whether cash consideration or shares swap and details of the same Cost of acquisition or the price at which the shares are acquired
1

	i)	Percentage of shareholding / control	Percentage of shareholding / control	100%.
		acquired and /or number of shares
		acquired
	j)	Brief background	about the entity	KAI was founded in 1986 and is based
		acquired in terms	of products /line of	in Maryland, USA.
		business acquired date of incorporation,
		history of last 3 years of turnover, country		The entity brings top of class offerings
		in which the entity	has presence and any	in three key areas: Clinical Trial
		other significant information (in brief)		Management, Clinical Research
				Consultation, and Data Management &
				Standardization. The entity has more
				than 30 years of experience in mental
				health, musculoskeletal diseases,
				neurology/CNS, and infectious
				diseases. The entity's staff is very
				experienced with over 66% being PhDs
				or MD/PhD and postgraduates in
				science.
				The revenues for the last three
				Financial years are as follows:
				• FY ended December 31, 2015 -
				USO 8.1 Million
				• FY ended December 31, 2016 -
				USO 8.9 Million
				• FY ended December 31, 2017 -
				USD 10.5 Million

Annexure - II

Details of acquisition DataCeutics

	Details of acquisition	DataCeutics
S.No a)	Particulars Name of the target entity and its brief details	Details DataCeutics is a specialty Clinical Functional Service Provider based in the USA, headquartered in Philadelphia, USA The company provides quality SAS based statistical programming, clinical reporting and clinical data managementprogramming.
b) c) d)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? Industry to which the entity belongs Objects and efects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	No. The target entity is in Life sciences industry. It provides Clinical Data Management services to the pharmaceutical industry. This acquisition strengthens TAKE's domain strength in Data Sciences specific to Life Sciences enabling us to partner with our clients providing much higher value adds in their Go-To­ Market strategy in terms of time, technology, and ease of change management to pharma & biotech companies that need to embrace emerging data sources that need a higher level of digital maturity. This acquisition also adds to thedepth of our Top-Pharma relationships in the US geography The addition to our team, 63% of whom are highly qualified with Doctoral or Masters degrees, also strengthens our Therapeutic experience in Oncology, CNS, Cardio-vascular, Neurology, Immunology. This acquisition would enable TAKE to offer more flexible and differentiated

==> picture [108 x 68] intentionally omitted <==

	Any Governmental or regulatory approvals required for the acquisition				business clientele.
e)					None.
f)	Indicative time period for completion of the acquisition Nature of Consideration- whether cash consideration or shares swap and details of the same Cost of acquisition or the price at which the shares are acquired
g)
h)
i)	Percentage of shareholding_I_control acquiredand/ornumber ofshares acquired				100%
j)	Brief background about the entity acquired in terms of products /line of business acquired date of incorporation, history of last 3 years of turnover, country in which the entity has presence and any other significant information (in brief) '				DataCeutics was founded in 1993 and is based in Philadelphia, USA. The company has core FSP experience inOncology,CNS, Cardio-vascular, Neurology, Immunology etc. The revenues for thelastthree Financial years are as follows: • FY ended December 31, 2015 - USO 18. 7 Million • FY ended December 31, 2016 - USO 20.1 Million • FY ended December 31, 2017 - USO 20.9 Million

==> picture [85 x 71] intentionally omitted <==

4